Surveillance for renal cell carcinoma: why and how? When and how often? (Q37261968)

19 August 2017

1 reference

title

Surveillance for renal cell carcinoma: why and how? When and how often? (English)

1 reference

19 August 2017

1 reference

Tobias Klatte

1

1 reference

19 August 2017

John S Lam

2

1 reference

19 August 2017

Brian Shuch

3

1 reference

19 August 2017

Arie S Belldegrun

4

1 reference

19 August 2017

Allan J Pantuck

5

1 reference

19 August 2017

3 December 2007

1 reference

19 August 2017

1 reference

19 August 2017

26

1 reference

19 August 2017

5

1 reference

19 August 2017

550-554

1 reference

19 August 2017

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (D

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Resection of metastatic renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Long-term results after pulmonary resection of renal cell carcinoma metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Renal Cell Carcinoma Recurrence After Nephrectomy for Localized Disease: Predicting Survival From Time of Recurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Stereotactic radiosurgery for brain metastasis from renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Gamma-knife radiosurgery for brain metastasis of renal cell carcinoma: results in 42 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Local Recurrence After Nephrectomy for Primary Renal Cancer: Computerized Tomography Recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Computerized tomography in the early postoperative management of renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.026

10.1016/J.UROLONC.2007.05.026

7 January 2021

Identifiers

DOI

1 reference

19 August 2017

1 reference